Back
HuagongsheHuagongshe Chemistry Print Report · For research reference only
HRID 85662Generated: October 29, 2026

Dimethylamine → 4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-(4-(dimethylcarbamoyl)piperidin-1-yl)ethylamino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoic acid

https://huagongshe.com/reaction/85662

Reaction equation

Participants

RoleNameHCIDCharge
ReactantDimethylamineHCID 674—
ReactantDiisopropylethylamineHCID 81531—
ReactantMethanaminium, N-((dimethylamino)(3H-1,2,3-triazolo(4,5-b)pyridin-3-yloxy)methylene)-N-methyl-, hexafluorophosphate(1-) (1:1)HCID 9886157—
ReactantHCID 68358209HCID 68358209—
Reactant4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-(dimethylamino)-2-oxoethylamino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoic acidHCID 86676593—
SolventDichloromethaneHCID 6344—
SolventEthyl AcetateHCID 8857—
Product4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-(4-(dimethylcarbamoyl)piperidin-1-yl)ethylamino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoic acidHCID 86762804—

Reaction Steps

To a solution of methyl 1-(2-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-9-(4-(methoxycarbonyl)phenyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-3a-ylamino)ethyl)piperidine-4-carboxylate (40 mg) in dioxane (1 mL) was added lithium hydroxide (2.7 mg, 0.112 mmol) in water (1 mL). A white precipitate was observed. The mixture was stirred at 25° C. for 3 hours. The desired product was observed at m/e 699.7 (M+H)+, 2.703 min, method 10. The reaction mixture was neutralized with 1 N HCl to pH-4 and diluted with methlylene chloride (10 mL). The organic layer was then collected, dried over sodium sulfate and filtered. After removal of solvent, the crude product was obtained as an oil (40 mg, ˜100%) which was used without further purification. Step 2. To a solution of 1-(2-(((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-9-(4-(methoxycarbonyl)phenyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-3a-yl)amino)ethyl)piperidine-4-carboxylic acid (40 mg, 0.057 mmol) in CH2Cl2 (5 ml) at rt was added dimethylamine (7.6 mg, 0.17 mmol) and HATU (65 mg, 0.18 mmol) followed by DIEA (29 mg, 0.23 mmol). The mixture was stirred for 3 hour at rt. The resulted mixture was diluted with ethyl acetate and washed with water. The organic layer was dried over sodium sulfate. The crude product was obtained after removal of solvent as a white solid (40 mg, ˜100%) which was used without further purification Step 3. 4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-(4-(dimethylcarbamoyl)piperidin-1-yl)ethylamino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoic acid was prepared following step 2 of the method described above for the synthesis of 4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-(dimethylamino)-2-oxoethylamino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoic acid. The product was isolated as a white solid (9 mg, 23.0%). LCMS: m/e 712.64 (M+H)+, 2.265 min (method 11). 1H NMR (400 MHz, METHANOL-d4) δ 7.95 (d, J=8.3 Hz, 2H), 7.25 (d, J=8.3 Hz, 2H), 5.33 (d, J=4.5 Hz, 1H), 4.87 (s, 1H), 4.74 (s, 1H), 3.65-3.38 (m, 6H), 3.16 (s, 3H), 3.05 (m, 2H), 2.96 (s, 3H), 2.75 (m, 1H), 2.23-1.85 (m, 11H), 1.82-1.74 (m, 6H), 1.70-1.48 (m, 9H), 1.44-1.28 (m, 3H), 1.22 (m, 4H), 1.13 (s, 3H), 1.08 (s, 3H), 1.00 (s, 3H), 0.98 (s, 3H),

Provenance & Evidence

DOI10.6084/m9.figshare.5104873.v1
Patent numberUS08846647B2
Source datasetuspto-grants-2014_09
ORD IDord-fa18351b66a14282ae5f58ab135f2eac
Source noteuspto-grants-2014_09